Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease

Fabry Disease Clinical Trial

Official title:

Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05698901
• Other study ID #: 22CT026be
• Status: Recruiting
• Start date: September 19, 2023
• Est. completion date: September 30, 2027

Study information

• Verified date: November 2023
• Source: Mackay Memorial Hospital
• Contact: Charles Jia-Yin Hou
• Phone: +886905960500
• Email: jiayinhou[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by deficient activity of the enzyme α-Gal A resulting from mutations affecting the GLA gene. It is characterized by severe multi-systemic involvement that leads to major organ failure and premature death in affected men and in some women. The α-Gal A deficiency results in progressive accumulation of un-degraded glycosphingolipids, predominantly globotriaosylceramide (Gb3), within cell lysosomes throughout the body.1 In patients at the fourth to fifth decade, left ventricular hypertrophy occur usually, and myocardial infarction and heart failure develops disease progress. Life-threatening renal, cardiac, and cerebrovascular diseases are added in later decades.2,3 Fabry disease is treatable with enzyme replacement therapy (ERT). Early recognition of symptoms and diagnosis of patients at a potentially reversible stage of the disease is therefore important. To date, plasma Lyso-Gb3 is useful in the diagnosis of Fabry disease. All male with classical Fabry disease could be discerned by an elevated plasma Lyso-GL-3; All adult female patients have elevated plasma Lyso-GL-3 above normal range.4 Other study also indicated that higher lyso-Gb3 concentrations at first visit were associated with a higher event rate in the past. Men with classical FD have higher Lyso-GL-3 values compared with patients with non-classical FD and women along with an increased risk of developing complications, more severe cardiac and renal disease.5 According to a publication from Taiwan society of cariology (TSOC) expert consensus, several cardiac biomarkers including N terminal pro B type natriuretic peptide (NT-proBNP) and cardiac troponin I/T (cTNI/cTNT) have been proposed to be alternative surrogate markers of cardiac involvement in FD.6However, there is no study to analyze the relationship between all these biomarkers including lyso-Gb3 and FD cardiac manifestation or improvement of cardiac damage outcomes under ERT yet. There is a high prevalence of the cardiac variant (IVS4+919G→A) (~1 in 1600 males) of FD in Taiwan as revealed by newborn screening programs7,8 and patients with idiopathic HCM.9 FD patients with cardiac variant need to fulfill at least two indicators as stated in "cardiac function assessment indicators of Fabry's disease cardiac variant type" with cardiac biopsy confirmed GL3 or lyso-Gb3 lipid accumulation to get local reimbursement for treatment. Cardiac biopsy is an invasive and relative dangerous procedure that some patients would refuse to take this procedure and could not get local reimbursement resulting in delay in treatment. Therefore in the present study the investigators are aiming to identify candidate biomarkers to establish a scoring algorithm for evaluating Fabry disease progression status or treatment response and the investigators could stage patient who with more correlated biomarkers at baseline would have higher risk to develop sever clinical outcome and initiate early therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: September 30, 2027
• Est. primary completion date: September 30, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years or older
• Male or female with Fabry disease diagnosed
• Presence of any one of following abnormal criteria of either: 1) Cardio-specific Biomarker; 2) Abnormal elevated value of plasma Gb3 or Lyso-Gb3; 3) Electrocardiography (ECG); 4) Cardio-specific Image.
• Group A: ERT Treatment naïve Fabry patients
• Group B: Agalsidase beta (ERT) exposed or treated Fabry patients
• Willing and able to comply with the required clinic visits, study procedures and assessments

Exclusion Criteria:

• Patient who are unwilling to sign inform consent form

Related Conditions & MeSH terms

• Fabry Disease

Intervention

Drug:
• Agalsidase beta
The treatment is following local reimbursement criteria and judge by physician

Locations

Country	Name	City	State
Taiwan	Charles Jia-Yin Hou	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Mackay Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To establish a comprehensive scoring algorithm to evaluate the disease progression status and potential indicators in response to treatment outcome mainly from imaging or biomarkers.		3 years
Secondary	(a)To figure out which biomarker and imaging data is statistically significant associated with disease progression status in patients without treatment.		3 years
Secondary	To further analyze and confirm from (a) that treatment outcomes (biomarkers/imaging parameters) of patient exposed to agalsidase beta therapy were statistically significant.		3 years